Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Aug 29;18(1):853.
doi: 10.1186/s12885-018-4765-z.

Contribution of KCTD12 to esophageal squamous cell carcinoma

Mohammad Reza Abbaszadegan  1   2 , Negin Taghehchian  1   2 , Liping Li  3 , Azadeh Aarabi  1 , Meysam Moghbeli  4
Affiliations

Contribution of KCTD12 to esophageal squamous cell carcinoma

Mohammad Reza Abbaszadegan et al. BMC Cancer. .

Abstract

Background: It has been shown that the expression of potassium channel tetramerization domain containing 12 (KCTD12) as a regulator of GABAB receptor signaling is reversely associated with gastrointestinal stromal tumors. In present study we examined the probable role of KCTD12 in regulation of several signaling pathways and chromatin remodelers in esophageal squamous cell carcinoma (ESCC).

Methods: KCTD12 ectopic expression was done in KYSE30 cell line. Comparative quantitative real time PCR was used to assess the expression of stem cell factors and several factors belonging to the WNT/NOTCH and chromatin remodeling in transfected cells in comparison with non-transfected cells.

Results: We observed that the KCTD12 significantly down regulated expression of NANOG, SOX2, SALL4, KLF4, MAML1, PYGO2, BMI1, BRG1, MSI1, MEIS1, EGFR, DIDO1, ABCC4, ABCG2, and CRIPTO1 in transfected cells in comparison with non-transfected cells. Migration assay showed a significant decrease in cell movement in ectopic expressed cells in comparison with non-transfected cells (p = 0.02). Moreover, KCTD12 significantly decreased the 5FU resistance in transfected cells (p = 0.01).

Conclusions: KCTD12 may exert its inhibitory role in ESCC through the suppression of WNT /NOTCH, stem cell factors, and chromatin remodelers and can be introduced as an efficient therapeutic marker.

Keywords: Chromatin remodeling; Esophageal cancer; NOTCH; Self-renewal; Stem cell; WNT.

PubMed Disclaimer

Conflict of interest statement

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Figures

Fig. 1
Fig. 1
KCTD12 ectopic expression and GFP expression using X-treme GENE HP DNA Transfection Reagent
Fig. 2
Fig. 2
Relative mRNA expression of stem cell factors in KCTD12 transfected in comparison with non-transfected cells
Fig. 3
Fig. 3
Relative mRNA expression of WNT and NOTCH signaling factors in KCTD12 transfected in comparison with non-transfected cells
Fig. 4
Fig. 4
Relative mRNA expression of chromatin remodeling factors in KCTD12 transfected in comparison with non-transfected cells
Fig. 5
Fig. 5
Relative mRNA expression of ABC transporters in KCTD12 transfected in comparison with non-transfected cells
Fig. 6
Fig. 6
Migration assay in KCTD12 transfected in comparison with non-transfected KSE30
Fig. 7
Fig. 7
Drug resistance assay for the 5FU in KCTD12 transfected cells in comparison with control
Fig. 8
Fig. 8
Probable correlations between KCTD12, NOTCH/WNT signaling pathways, chromatin remodelers, and HOX genes in esophageal squamous cell carcinoma
See this image and copyright information in PMC

References

    1. Ferlay J, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127(12):2893–2917. doi: 10.1002/ijc.25516. - DOI - PubMed
    1. Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol. 2006;24(14):2137–2150. doi: 10.1200/JCO.2005.05.2308. - DOI - PubMed
    1. Mahboubi E, et al. Oesophageal cancer studies in the Caspian littoral of Iran: the Caspian cancer registry. Br J Cancer. 1973;28(3):197–214. doi: 10.1038/bjc.1973.138. - DOI - PMC - PubMed
    1. Dipetrillo T, et al. Neoadjuvant paclitaxel poliglumex, cisplatin, and radiation for esophageal cancer: a phase 2 trial. Am J Clin Oncol. 2012;35(1):64–67. doi: 10.1097/COC.0b013e318201a126. - DOI - PubMed
    1. van Hagen P, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012;366(22):2074–2084. doi: 10.1056/NEJMoa1112088. - DOI - PubMed

MeSH terms